Literature DB >> 12808324

Active immunization using dendritic cells mixed with tumor cells inhibits the growth of lymphomas.

Jin Ny Park1, Cheolwon Suh, Jehoon Yang, Jung Sun Park, Keon Uk Park, Young Joo Min, Hyo Jung Kim, Young-Hoon Kim, Sang-Hee Kim.   

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells for the induction and activation of cytotoxic T lymphocytes. We tested whether bone marrow-derived DCs are capable of inducing protective immunity against a murine lymphoma (A20). DCs were grown from tumor-bearing BALB/c mice by culturing bone marrow cells. BALB/c mice were injected (sc) with A20 cells on day 0. Intraperitoneal immunization with DCs mixed with lethally irradiated A20 cells were started when the tumor reached ca. 4-5 mm in diameter (Group A) or on day -7 (Group B). Booster immunizations were given every 3-4 days for four weeks. By 31 days in group A, there was a significant reduction in tumor growth in the mice immunized with DCs mixed with irradiated A20 cells as compared with the control groups (p=0.016). In group B, tumor growth was completely inhibited and there was no tumor growth following extended observations after completion of immunization. Thus, DCs mixed with irradiated tumor cells can induce an antitumor effect. This provides a rationale for the use of DCs mixed with irradiated tumor cells in immunotherapy for minimal residual disease of lymphomas.

Entities:  

Mesh:

Year:  2003        PMID: 12808324      PMCID: PMC3055039          DOI: 10.3346/jkms.2003.18.3.372

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  1 in total

1.  Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.

Authors:  So Mi Oh; Keunhee Oh; Dong-Sup Lee
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.